Printer Friendly Version View printer-friendly version
<< Back

Cidara Therapeutics Announces Presentations at IDWeek 2017 and the 8th Trends in Medical Mycology Meeting

Data Highlight Advantages of CD101 in Difficult-to-Treat Infections

SAN DIEGO, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data from preclinical studies evaluating its novel echinocandin antifungal CD101 will be presented at two upcoming infectious disease meetings. CD101 abstracts have been accepted for presentation at both IDWeek 2017 in San Diego from October 4-8 and at the 8th Trends in Medical Mycology (TIMM) meeting in Belgrade, Serbia from October 6-9.

A total of six presentations will highlight the unique attributes of CD101, Cidara’s lead antifungal drug candidate and the only long-acting antifungal in the echinocandin class. Specifically, data to be presented will showcase the potential advantages of CD101, which has exhibited the following characteristics: in vivo activity against emerging resistant organisms; high target-attainment and exposure to treat less susceptible pathogens; superior tissue penetration compared to micafungin; and biofilm activity.

“These presentations reflect our comprehensive program to build the foundation of a superior antifungal profile for CD101,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “We are excited to share these findings with medical professionals to reinforce our commitment to provide new options for patients with deadly invasive fungal infections.”

Details of the Cidara IDWeek and TIMM presentations are as follows:

IDWeek 2017 Presentations

Friday, October 6: Poster Abstract Session – Preclinical study with new antibiotics and antifungals (12:30 p.m.2:00 p.m. PT, San Diego Convention Center, Poster Hall CD)

  • 1518: Evaluation of the Efficacy of CD101, a Novel Echinocandin, in the Treatment of Candida auris Infection Using a Murine Model of Disseminated Candidiasis; C. Hager, et. al.
  • 1528: In vivo Pharmacokinetic/Pharmacodynamic (PK/PD) Target Characterization of the Novel, Long Acting Echinocandin CD101 against C. albicans and C. glabrata in the Neutropenic Murine Disseminated Candidiasis Model; A. J. Lepak, et. al.
  • 1533: Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-Abdominal Abscess Model; Y. Zhao, et. al.

2017 TIMM Presentations

Saturday, October 7: Poster Session (11:00 a.m.12:00 p.m. CEST, Sava Centre Congress Center, Poster Area)

  • P057: Evaluate the Ability of CD101 to Prevent and Treat Candida albicans Biofilms and Explore its Temporal Effect by Time Lapse Photography; J. Chandra, et. al.
  • P349: PK/PD Target Characterization of the Novel Echinocandin CD101 Against Candida spp. in a Neutropenic Mouse Model of Disseminated Candidiasis; A. J. Lepak, et. al.

Sunday, October 8: Session S15: New antifungal drugs in the pipeline (2:15 p.m.4:00 p.m. CEST, Sava Centre Congress Center)

  • S15.2 (2:27 p.m.): CD101; T. Sandison

Copies of these posters and presentations will be available on the Cidara website following the meetings: http://www.Cidara.com/

About Fungal Infections

Approximately 97,000 Americans die from hospital-related fungal infections each year and 90 percent of these infections are caused by two common fungi, Candida and Aspergillus. The emergence of a new and virulent fungal pathogen called Candida auris (C. auris) is also an emerging public health threat due to its resistance to existing antifungal agents. As of July 2017, the Centers for Disease Control and Prevention (CDC) reports that C. auris has been identified in more than 200 patients in the United States. Cidara is currently evaluating CD101 in C. auris, in addition to multiple other invasive fungal infections.

About Cidara Therapeutics

Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, CD101 IV, through Phase 2 and developing CD201, its bispecific antibiotic immunotherapy, for the treatment of multi-drug resistant Gram-negative bacterial infections. CD101 IV has improved pharmacokinetics compared to existing echinocandins and has the potential for expanded utility across patient settings. CD101 IV is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal infections. CD201 is the first drug candidate selected from Cidara’s novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara has received a grant for up to $6.9 million from CARB-X (Combating Antibiotic Resistant Bacteria Accelerator) to advance the development of CD201. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the potential advantages, effectiveness, safety, and other attributes of CD101 and other potential product candidates, including the potential for these compounds to successfully treat or prevent infections, including those caused by resistant pathogens, and potentially transform the way infectious diseases are treated, and the potential for the Cloudbreak platform to result in future drug candidates. Risks that contribute to the uncertain nature of the forward-looking statements include: the success and timing of Cidara’s preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; changes in Cidara’s plans to develop and commercialize its product candidates; Cidara’s ability to obtain additional financing; Cidara’s ability to obtain and maintain intellectual property protection for its product candidates; and the loss of key scientific or management personnel. These and other risks and uncertainties are described more fully in Cidara’s Form 10-Q most recently filed with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Cidara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

INVESTOR CONTACT:
Robert H. Uhl
Westwicke Partners, LLC
Managing Director
(858) 356-5932
robert.uhl@westwicke.com

MEDIA CONTACT:
Christy Curran
Sam Brown Inc.
615-414-8668
ChristyCurran@sambrown.com

Primary Logo

Cidara Therapeutics, Inc.